Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S) Norman Wasel Diamant Thaçi Lars E. French Curdin Conrad Yves Dutronc Gaia Gallo Lovisa Berggren Jean-Philippe Lacour 10.6084/m9.figshare.12179274.v1 https://adisjournals.figshare.com/articles/figure/Ixekizumab_and_Ustekinumab_Efficacy_in_Nail_Psoriasis_in_Patients_with_Moderate-to-Severe_Psoriasis_52-Week_Results_from_a_Phase_3_Head-to-Head_Study_IXORA-S_/12179274 <p>The above Summary Slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020.<b> </b></p> 2020-05-11 10:17:25 Ixekizumab Nail psoriasis Psoriasis Ustekinumab